R

R&G PharmaStudies Co Ltd
SZSE:301333

Watchlist Manager
R&G PharmaStudies Co Ltd
SZSE:301333
Watchlist
Price: 49.6 CNY -4.39% Market Closed
Market Cap: 4.8B CNY
Have any thoughts about
R&G PharmaStudies Co Ltd?
Write Note

R&G PharmaStudies Co Ltd
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

R&G PharmaStudies Co Ltd
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
R
R&G PharmaStudies Co Ltd
SZSE:301333
Other Current Liabilities
ÂĄ221.3m
CAGR 3-Years
21%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Other Current Liabilities
ÂĄ6.4B
CAGR 3-Years
3%
CAGR 5-Years
16%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Other Current Liabilities
ÂĄ1.7B
CAGR 3-Years
8%
CAGR 5-Years
31%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Other Current Liabilities
ÂĄ4.5B
CAGR 3-Years
12%
CAGR 5-Years
36%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Other Current Liabilities
ÂĄ1.4B
CAGR 3-Years
20%
CAGR 5-Years
23%
CAGR 10-Years
35%
W
WuXi XDC Cayman Inc
HKEX:2268
Other Current Liabilities
ÂĄ582.8m
CAGR 3-Years
211%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

R&G PharmaStudies Co Ltd
Glance View

Market Cap
4.8B CNY
Industry
Life Sciences Tools & Services

R&G PharmaStudies Co., Ltd. engages in the provision of clinical trial outsourcing services. The company is headquartered in Beijing, Beijing and currently employs 1,926 full-time employees. The company went IPO on 2022-08-02. The firm's main businesses include clinical trial operation services (CO Services), clinical trial site management services (SMO Services), biological sample testing services (BA Services), data management and statistical analysis services (DM/ST Services), clinical trials Consulting Services, Clinical Pharmacology Services (CP Services) and others. The firm operates its businesses primarily in the domestic market.

Intrinsic Value
59.36 CNY
Undervaluation 16%
Intrinsic Value
Price
R

See Also

What is R&G PharmaStudies Co Ltd's Other Current Liabilities?
Other Current Liabilities
221.3m CNY

Based on the financial report for Dec 31, 2023, R&G PharmaStudies Co Ltd's Other Current Liabilities amounts to 221.3m CNY.

What is R&G PharmaStudies Co Ltd's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 3Y
21%

Over the last year, the Other Current Liabilities growth was 15%. The average annual Other Current Liabilities growth rates for R&G PharmaStudies Co Ltd have been 21% over the past three years .

Back to Top